Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.

Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L.

Br J Cancer. 2014 Nov 11;111(10):1909-16. doi: 10.1038/bjc.2014.503. Epub 2014 Oct 28. Erratum in: Br J Cancer. 2014 Dec 9;111(12):2383.

PMID:
25349968
[PubMed - indexed for MEDLINE]
2.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV.

Lancet Oncol. 2012 Aug;13(8):827-37. doi: 10.1016/S1470-2045(12)70241-3. Epub 2012 Jul 2.

PMID:
22759480
[PubMed - indexed for MEDLINE]
3.

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.

Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS.

BMC Cancer. 2012 Jan 14;12:16. doi: 10.1186/1471-2407-12-16.

PMID:
22244160
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Predictive genomic biomarkers.

Kumar R, Amado RG.

Curr Top Microbiol Immunol. 2012;355:173-88. doi: 10.1007/82_2011_164. Review.

PMID:
21877260
[PubMed - indexed for MEDLINE]
5.

Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients.

Gomes AS, Rosove MH, Rosen PJ, Amado RG, Sayre JW, Monteleone PA, Busuttil RW.

AJR Am J Roentgenol. 2009 Dec;193(6):1665-71. doi: 10.2214/AJR.08.1806.

PMID:
19933662
[PubMed - indexed for MEDLINE]
6.

An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.

Stephenson JJ, Gregory C, Burris H, Larson T, Verma U, Cohn A, Crawford J, Cohen RB, Martin J, Lum P, Yang X, Amado RG.

Clin Colorectal Cancer. 2009 Jan;8(1):29-37. doi: 10.3816/CCC.2009.n.005.

PMID:
19203894
[PubMed - indexed for MEDLINE]
7.

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG.

Cancer. 2009 Apr 1;115(7):1544-54. doi: 10.1002/cncr.24088.

PMID:
19189371
[PubMed - indexed for MEDLINE]
Free Article
8.

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG.

J Clin Oncol. 2009 Feb 10;27(5):672-80. doi: 10.1200/JCO.2008.19.8135. Epub 2008 Dec 29.

PMID:
19114685
[PubMed - indexed for MEDLINE]
Free Article
9.

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.

Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG.

Clin Colorectal Cancer. 2008 May;7(3):184-90. doi: 10.3816/CCC.2008.n.024.

PMID:
18621636
[PubMed - indexed for MEDLINE]
10.

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.

Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW.

Liver Int. 2009 Feb;29(2):284-90. doi: 10.1111/j.1478-3231.2008.01762.x. Epub 2008 May 14.

PMID:
18482274
[PubMed - indexed for MEDLINE]
11.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

PMID:
18316791
[PubMed - indexed for MEDLINE]
Free Article
12.

Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.

Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA.

Clin Cancer Res. 2008 Jan 15;14(2):502-8. doi: 10.1158/1078-0432.CCR-07-1509.

PMID:
18223225
[PubMed - indexed for MEDLINE]
Free Article
13.

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG.

Br J Cancer. 2007 Dec 3;97(11):1469-74. Epub 2007 Nov 27.

PMID:
18040272
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Influence of roasting conditions on the acrylamide content and the color of roasted almonds.

Lukac H, Amrein TM, Perren R, Conde-Petit B, Amadò R, Escher F.

J Food Sci. 2007 Jan;72(1):C033-8.

PMID:
17995869
[PubMed - indexed for MEDLINE]
15.

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.

Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G.

Nat Biotechnol. 2007 Oct;25(10):1134-43.

PMID:
17921999
[PubMed - indexed for MEDLINE]
16.

Occurrence of acrylamide in selected foods and mitigation options.

Amrein TM, Andres L, Escher F, Amadò R.

Food Addit Contam. 2007;24 Suppl 1:13-25. Review.

PMID:
17687696
[PubMed - indexed for MEDLINE]
17.

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M.

Ann Oncol. 2008 Jan;19(1):92-8. Epub 2007 Sep 4.

PMID:
17785764
[PubMed - indexed for MEDLINE]
Free Article
18.

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.

Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ.

Cancer. 2007 Sep 1;110(5):980-8.

PMID:
17671985
[PubMed - indexed for MEDLINE]
Free Article
19.

Fermentation of resistant starches: influence of in vitro models on colon carcinogenesis.

Fässler C, Gill CI, Arrigoni E, Rowland I, Amadò R.

Nutr Cancer. 2007;58(1):85-92.

PMID:
17571971
[PubMed - indexed for MEDLINE]
20.

Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, Yang L, Amado RG, Hecht JR.

Clin Colorectal Cancer. 2007 Mar;6(6):427-32.

PMID:
17531105
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk